Ipsen's Sales Growth Could Be Held Back By Generics And Currency In 2021
Dysport Down Due To COVID-19
France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.
You may also be interested in...
Advanz has claimed a first with a European launch of a rival to Ipsen’s Somatuline, introducing its generic lanreotide in Germany under the name Mytolac.
Ipsen has gained worldwide development and commercialization rights to IRLAB’s dopamine D3 antagonist, mesdepotem, in levodopa-induced dyskinesia in Parkinson’s disease.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.